Indaptus Therapeutics is trading 10.52% lower at $3.44, with no new company-specific announcement identified to explain the September 28, 2026 decline.
- The previously reported private placement is not a new catalyst.
- Broader risk-off sentiment may be adding pressure, with major indexes down amid renewed geopolitical and oil-price concerns; this is possible context, not a confirmed explanation for the stock’s move.